Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors -: The role of receptor activity modifying protein 1

被引:81
作者
Hay, Debbie L.
Christopoulos, George
Christopoulos, Arthur
Sexton, Patrick M. [1 ]
机构
[1] Monash Univ, Dept Pharm, Drug Discovery Biol Lab, Clayton, Vic 3800, Australia
[2] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand
关键词
D O I
10.1124/mol.106.027953
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
1-Piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl] carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl) methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)quinazolinyl) (BIBN4096BS), a calcitonin gene-related peptide (CGRP) receptor antagonist, can alleviate the symptoms of migraine and is highly selective for CGRP over adrenomedullin (AM) receptors. These receptors are heterodimers of the calcitonin receptor-like receptor (CL) and receptor activity modifying proteins (RAMPs), with the pharmacological properties determined by the RAMP subunit. BIBN4096BS-sensitive CGRP1 receptors are CL/RAMP1, whereas BIBN4096BS-insensitive AM receptors are CL/RAMP2 or CL/RAMP3 (AM(1) and AM(2), respectively), implicating RAMP1 in conferring BIBN4096BS sensitivity. Because calcitonin receptors [CT(a)] also interact with RAMP1 [AMY(1(a)) receptors], BIBN4096BS could also have affinity for these receptors. To test this, receptors were transfected into COS-7 cells and agonist-stimulated cAMP levels measured in the presence and absence of antagonists. We found that AMY(1(a)) receptors were similar to 150-fold less sensitive to BIBN4096BS antagonism than CGRP1 receptors. In contrast, AMY(3(a)) [CT(a)/RAMP3] or AM(2) receptors were not sensitive to BIBN4096BS antagonism. We investigated Trp74 in RAMP1, a residue implicated in the species selectivity of BIBN4096BS. BIBN4096BS affinity was reduced at AMY(1(a)) and CGRP1 receptors when this residue was mutated to lysine or alanine. The equivalent residue in RAMP3, Glu74, when mutated to tryptophan (E74W), induced BIBN4096BS sensitivity at AM(2) and AMY(3(a)) receptors. It is interesting that a selective reduction in AM potency was observed at E74W AM(2) receptors, implicating this residue in AM interactions with this receptor. These data support the importance of Trp74 in RAMP1 in the interaction of BIBN4096BS with CGRP(1) and AMY (1(a)) receptors and identified Glu74 in RAMP3 as the first amino acid in RAMP important for agonist interactions with calcitonin-family receptors.
引用
收藏
页码:1984 / 1991
页数:8
相关论文
共 27 条
[1]
Pharmacology of the human CGRP1 receptor in Cos 7 cells [J].
Bailey, Richard J. ;
Hay, Debbie L. .
PEPTIDES, 2006, 27 (06) :1367-1375
[2]
INVESTIGATION AND CHARACTERIZATION OF BINDING-SITES FOR ISLET AMYLOID POLYPEPTIDE IN RAT MEMBRANES [J].
BHOGAL, R ;
SMITH, DM ;
BLOOM, SR .
ENDOCRINOLOGY, 1992, 130 (02) :906-913
[3]
Vascular actions of calcitonin gene-related peptide and adrenomedullin [J].
Brain, SD ;
Grant, AD .
PHYSIOLOGICAL REVIEWS, 2004, 84 (03) :903-934
[4]
Novel receptor partners and function of receptor activity-modifying proteins [J].
Christopoulos, A ;
Christopoulos, G ;
Morfis, M ;
Udawela, M ;
Laburthe, M ;
Couvineau, A ;
Kuwasako, K ;
Tilakaratne, N ;
Sexton, PM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (05) :3293-3297
[5]
G protein-coupled receptor allosterism and complexing [J].
Christopoulos, A ;
Kenakin, T .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :323-374
[6]
Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product [J].
Christopoulos, G ;
Perry, KJ ;
Morfis, M ;
Tilakaratne, N ;
Gao, YY ;
Fraser, NJ ;
Main, MJ ;
Foord, SM ;
Sexton, PM .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :235-242
[7]
HUMAN INTESTINAL VIP RECEPTOR - CLONING AND FUNCTIONAL EXPRESSION OF 2 CDNA-ENCODING PROTEINS WITH DIFFERENT N-TERMINAL DOMAINS [J].
COUVINEAU, A ;
ROUYERFESSARD, C ;
DARMOUL, D ;
MAORET, JJ ;
CARRERO, I ;
OGIERDENIS, E ;
LABURTHE, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (02) :769-776
[8]
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist [J].
Doods, H ;
Hallermayer, G ;
Wu, DM ;
Entzeroth, M ;
Rudolf, K ;
Engel, W ;
Eberlein, W .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (03) :420-423
[9]
Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache - Therapeutic implications [J].
Edvinsson, L .
CNS DRUGS, 2001, 15 (10) :745-753
[10]
The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor [J].
Fraser, NJ ;
Wise, A ;
Brown, J ;
McLatchie, LM ;
Main, MJ ;
Foord, SM .
MOLECULAR PHARMACOLOGY, 1999, 55 (06) :1054-1059